Compugen (CGEN +3.1%) announces that it will "significantly" broaden its monoclonal antibody...

|About: Compugen Ltd. (CGEN)|By:, SA News Editor

Compugen (CGEN +3.1%) announces that it will "significantly" broaden its monoclonal antibody program and will establish preclinical development capabilities in-house instead of using third parties. The firm will take on $8M in funding from Israel-based Baize Investments to help move along its research program.